A citation-based method for searching scientific literature


List of co-cited articles
1394 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
78




A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
176
37

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
36

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
129
34

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Ruggero Galici, Carrie K Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G Echemendia, Lilly C Williams, Tomas de Paulis, P Jeffrey Conn. J Pharmacol Exp Ther 2006
129
31




Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
563
25

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
25

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
Michael P Johnson, David Barda, Thomas C Britton, Renee Emkey, William J Hornback, G Erik Jagdmann, David L McKinzie, Eric S Nisenbaum, Joseph P Tizzano, Darryle D Schoepp. Psychopharmacology (Berl) 2005
126
24

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
147
24

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
24

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
127
21


Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.
Guy A Higgins, Theresa M Ballard, James N C Kew, J Grayson Richards, John A Kemp, Geo Adam, Thomas Woltering, Shigetada Nakanishi, Vincent Mutel. Neuropharmacology 2004
132
20

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro, Gerard J Marek, Eric S Nisenbaum, John T Catlow, Ann E Kingston, Deborah D Giera,[...]. J Pharmacol Exp Ther 2007
80
25



Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
297
19

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
72
26


Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
18

Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition.
Guibao Gu, Daniel S Lorrain, Hongbing Wei, Rebecca L Cole, Xin Zhang, Lorrie P Daggett, Herve J Schaffhauser, Linda J Bristow, Sandra M Lechner. Brain Res 2008
76
22

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.
Michael P Johnson, Melvyn Baez, G Erik Jagdmann, Thomas C Britton, Thomas H Large, David O Callagaro, Joseph P Tizzano, James A Monn, Darryle D Schoepp. J Med Chem 2003
150
17

The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.
Corrado Corti, Giuseppe Battaglia, Gemma Molinaro, Barbara Riozzi, Anna Pittaluga, Mauro Corsi, Manolo Mugnaini, Ferdinando Nicoletti, Valeria Bruno. J Neurosci 2007
159
17

Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
417
17

CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
67
25



Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
16


LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Darryle D Schoepp, Rebecca A Wright, Louise R Levine, Brenda Gaydos, William Z Potter. Stress 2003
173
16

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.
Mitsumasa Kurita, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, Nagahide Takahashi,[...]. Nat Neurosci 2012
177
16

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.
P Jeffrey Conn, Arthur Christopoulos, Craig W Lindsley. Nat Rev Drug Discov 2009
771
15

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
G J Marek, R A Wright, D D Schoepp, J A Monn, G K Aghajanian. J Pharmacol Exp Ther 2000
227
15


Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Chad J Swanson, Mark Bures, Michael P Johnson, Anni-Maija Linden, James A Monn, Darryle D Schoepp. Nat Rev Drug Discov 2005
464
15

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.
Miguel Fribourg, José L Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K Adney, Candice Hatcher, José M Eltit,[...]. Cell 2011
194
15

Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats.
Agnieszka Nikiforuk, Piotr Popik, Karla U Drescher, Marcel van Gaalen, Ana-Lucia Relo, Mario Mezler, Gerard Marek, Hans Schoemaker, Gerhard Gross, Anton Bespalov. J Pharmacol Exp Ther 2010
59
23

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Chantal Schlumberger, Daniela Schäfer, Caroline Barberi, Lorenzo Morè, Jens Nagel, Małgorzata Pietraszek, Werner J Schmidt, Wojciech Danysz. Behav Pharmacol 2009
68
20


LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
A E Kingston, P L Ornstein, R A Wright, B G Johnson, N G Mayne, J P Burnett, R Belagaje, S Wu, D D Schoepp. Neuropharmacology 1998
311
14


Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
76
18

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
13

Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Daniel S Lorrain, Hervé Schaffhauser, Una C Campbell, Christopher S Baccei, Lucia D Correa, Blake Rowe, Dana E Rodriguez, Jeffery J Anderson, Mark A Varney, Anthony B Pinkerton,[...]. Neuropsychopharmacology 2003
80
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.